>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance:
  • HTGM -19.7%, (to offer 10 mln shares of its common stock in an underwritten public offering; updates guidance), ATEN -19.3%,HIVE -18.4%, SQNS -11.7%, (commences offering of ADS; updaates guidance), PSO -6%, ETH -5.9%, (Ethan Allen modestly lower following Q2 update -- sees Q2 adj EPS of $0.51-0.52 vs. $0.52 CapIQ Consensus, sales +2% to $198.5 mln vs. $212.06 estimate, gross margin of 54.3%), RNST -4.6%, F -4%, IBKR -3.1%,FAST -2%, CSX -0.7%
M&A news:
  • CELG -1.5% (WSJ reporting CELG / JUNO in merger talks)
Other news:
  • GNCA -27.3% (announces proposed concurrent public offerings of common stock and Class A warrants and Series A convertible preferred stock and Class A warrants), HALO -13.4% (being attributed to SWOG abstract)
  • OBLN -11.7% (commences an underwritten public offering of $35 mln of shares of its common stock)
  • ADNT -8.1% (Adient & Boeing form JV to develop, manufacture and sell a portfolio of seating products to airlines and aircraft leasing companies)
  • ASIX -5.7% (experiences temporary production issue at its Hopewell, Virginia facility related to the recent severe winter weather; expects to incur an approximately $30-35 million unfavorable impact to pre-tax income in the 1Q18)
  • XON -5.6% (commenced an underwritten public offering of shares of its common stock)
  • BOOT -5% (launches public offering of 5.5 mln shares of common stock held by stockholders; provides guidance in connection with offering)
  • URGN -3.2% (commences 1,135,847 common stock offering)
  • NTNX -3.1% (to offer $400 mln aggregate principal amount of convertible senior notes due 2023 in a private placement)
  • BGNE -2.8% (to offer and sell $650 mln of its ADSs)
  • NRZ -2.6% (commences 25 mln common stock offering; updates guidance as part of a previously announced public offering)
  • GDEN -1.6% (commences secondary public offering of 6.5 mln shares of common stock to be sold by shareholders)
  • PATK -1.4% (to offer $125 mln aggregate principal amount of its convertible senior notes due 2023 in a private placement)
Analyst comments:
  • HPQ -0.7% (downgraded to Equal Weight at Barclays)
  • GG -1.2% (downgraded to Hold at Canaccord Genuity)
  • DISH -1.5% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
  • NUVA -1.9% (downgraded to Market Perform from Outperform at Wells Fargo )
  • JNPR -2% (downgraded to Equal Weight at Barclays)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:
  • ASML +6.7%, ORBK +3.4%, PNFP +1%, USB +0.9%, BAC +0.5%
M&A news:
  • JUNO +59.5% (WSJ reporting CELG / JUNO in merger talks)
Select Juno peers showing strength:
  • ADAP +8.4%, BLUE +7.1%, BLCM +6.4%, ZIOP +3.8%, GILD +0.5%
Other news:
  • NURO +72.7% (announces collaboration with GlaxoSmithKline (GSK) involving Quell Wearable Pain Relief Technology; GSK to pay the co $5 mln and up to $21.5 mln in milestones)
  • AEZS +37.7% (enters into licensing and assignment agreement with Strongbridge (SBBP) for Macrilen (macimorelin) in the U.S. and Canada)
  • NEWA +14.6% (Newater Technology +25% after announcing new strategic partnership with NW Blockchain Limited to jointly develop blockchain applications to use in the wastewater treatment industry)
  • ONTX +11.5% (announces that it is moving forward with its Phase 3 INSPIRE pivotal trial following the promising interim analysis)
  • VRS +9.7% (expanded its evaluation of potential transaction alternatives to include other alternatives, including but not limited to, a potential sale or merger of the entire company)
  • BLRX +6.5% (announces partial monotherapy results from Phase 2a COMBAT study in pancreatic cancer)
  • SEII +6.2% (entered into a cooperation agreement with CoAssets Pte for the development of a blockchain-enabled financial transaction system and mobile application)
  • TAT +5.7% (TransAtlantic Petroleum has formed strategic committee and engaged financial advisor to market the Company and explore strategic alternatives)
  • EGO +4.4% (reports 2017 gold production of 285,919 ounces vs revised guidance of 280,000-310,000 ounces and prelim 2018 guidance; suspending cash payment of semi-annual dividend payment )
  • EXEL +2.7% ( Ph 3 Trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma)
Analyst comments:
  • IBM +1.9% (upgraded to Overweight at Barclays)
  • GRPN +1.6% (upgraded to Neutral from Sell at Goldman)
  • LLL +0.8% (upgraded to Buy from Neutral at BofA/Merrill)
  • BLL +0.6% (upgraded to Buy from Neutral at Citigroup)